| Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? | |
| | |
MedLine Citation:
|
PMID: 20042226 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate if the use of diagnostic FDG-PET/CT leads to stage migration in patients with advanced ovarian cancer and to evaluate the prognostic significance of FDG-PET/CT. METHODS: From September 2004 to August 2007, 201 patients with a Risk of Malignancy Index (RMI) >150 based on serum CA-125, ultrasound examinations and menopausal state, underwent PET/CT within 2 weeks prior to standard surgery/debulking of a pelvic tumor. On 15 August, 2009 overall survival and prognostic variables were analysed in 66 ovarian cancer patients (64 stage III and 2 stage IV). RESULTS: Median follow-up was 30.2 months; median age was 62.5 years (range 35-85 years); 97% (64/66) had a performance status <or=2; 38% (25/66) underwent complete debulking (no macroscopic residual tumor); 51% (39/66) was diagnosed with PET/CT stage III and 41% (27/66) was diagnosed with PET/CT stage IV. Survival was significantly longer for patients with PET/CT stage III than for patients with PET/CT stage IV (P=0.03). Using univariate analysis, PET/CT stage III (P=0.03), complete debulking (no macroscopic residual tumor) (P=0.002), and GOG performance status <or=2 (P=0.04) were statistically significant prognostic variables. Using multivariate Cox regression analysis, complete debulking was the only statistically significant independent prognostic variable (P=0.02). CONCLUSION: In primary advanced ovarian cancer the use of diagnostic FDG-PET/CT leads to stage migration. Adequate staging is the foundation for ovarian cancer treatment and advanced imaging for optimal evaluation of metastases should be promoted in clinical trials. The strongest determinant of patient outcome is residual abdominal tumor after primary surgery. |
| | |
Authors:
|
S Risum; C H?gdall; A Loft; A K Berthelsen; E H?gdall; L Nedergaard; L Lundvall; S A Engelholm |
Related Documents
:
|
20091186 - Fdg-pet and other imaging modalities for the evaluation of breast cancer recurrence and... 16330566 - Use of a decision analysis model to assess the cost-effectiveness of 18f-fdg pet in the... 17198346 - Automated interpretation of pet/ct images in patients with lung cancer. 8306836 - Positron emission tomography for preoperative staging of colorectal carcinoma. 21538566 - Swelling around a child's knee. 7849376 - Contrast-enhanced magnetic resonance imaging of the lumbosacral roots in the dysimmune ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2009-12-29 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 116 ISSN: 1095-6859 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-15 Completed Date: 2010-03-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 395-8 Citation Subset: IM |
Affiliation:
|
Department of Oncology, the Finsen Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. signerisum@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over CA-125 Antigen / blood Female Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplasm Staging Ovarian Neoplasms / blood, pathology, radionuclide imaging*, surgery Positron-Emission Tomography / methods* Prognosis Prospective Studies Radiopharmaceuticals / diagnostic use* Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/CA-125 Antigen; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study fro...
Next Document: 16.Secondary immunodeficiencies, including HIV infection.